proteome profiler antibody based angiogenesis  (R&D Systems)

Journal: PLoS ONE

Article Title: Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

doi: 10.1371/journal.pone.0180297

Figure Lengend Snippet: A, Bazedoxifene inhibits tube formation. HUVECs were seeded on Matrigel-coated wells with VEGF (10 ng/ml) in the absence or in the presence of Bazedoxifene and incubated for 24 hours to form a capillary network. The total number of branched tubes was then counted and representative image of capillary network formation was taken. B, Bazedoxifene downregulates several angiogenic factors in vitro . The proteome profiler antibody angiogenesis array was performed. The relative level of selected angiogenesis-related proteins was determined in parallel between untreated (left) and treated (right) HUVEC cells. C, Bazedoxifene inhibits endothelial cellular invasion. HUVECs (1 × 10 6 cells/ml) were added to transwell chamber coated with Matrigel and treated with VEGF (20 ng/ml) in the absence or in presence of Bazedoxifene. After 24 hours, the number of invaded cells was counted, and results are expressed as percentage of invasion (basal invasion with no treatment). D, Bazedoxifene blocks rhabdomyosarcoma cells invasion. Parental RH30 and RH28 cells were starved in 0% FBS medium for 24 hours. After that, cells were seeded (5 × 10 4 cells/well) to the top chamber, and 10% FBS was added into the lower chamber. Cells were treated with Bazedoxifene for 24 hours, and then invasion cells were detected in the bottom chamber using a Cultrex BME Cell Invasion Assay. Statistical analysis of three independent experiments was shown as means, *, P < 0.05.

Article Snippet: Proteome profiler antibody based Angiogenesis array (R & D systems; Cat. No. ARY007) was used according to manufacturer’s instructions to detect the relative levels of expression of angiogenesis related proteins in control and Bazedoxifene treated cells.

Techniques: Incubation, In Vitro, Invasion Assay